CCA
EWTX icon

Cygnus Capital Advisors’s Edgewise Therapeutics EWTX Stock Holding History

Cygnus Capital Advisors’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-3,427
Closed -$108K – 81
2026
Q1 		$108K Hold
3,427
– – 0.07% 61
2025
Q4 		$85K Buy
+3,427
New +$68.8K 0.06% 61

Other funds holding EWTX

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Cygnus Capital Advisors's EWTX Position: Q2 2026 in Review

Cygnus Capital Advisors sold out of Edgewise Therapeutics (EWTX) in Q2 2026, closing a stake of 3,427 shares — an estimated $108K sold.

Cygnus Capital Advisors first reported a position in EWTX in Q4 2025 and held it in 2 quarters. The position peaked at $108K in Q1 2026. 226 funds tracked by Wall St. Rank hold EWTX as of Q2 2026.

  • Cygnus Capital Advisors reported no remaining Edgewise Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Cygnus Capital Advisors sold 3,427 Edgewise Therapeutics shares in Q2 2026, an estimated $108K.
  • Cygnus Capital Advisors first reported a position in Edgewise Therapeutics in Q4 2025 and held it in 2 quarters.
  • Cygnus Capital Advisors's Edgewise Therapeutics position peaked at $108K in Q1 2026.
  • 226 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q2 2026.

Based on Cygnus Capital Advisors's 13F filing for Q2 2026, filed 3 Sep 2026.